ESTRO 38 Abstract book

S813 ESTRO 38

within the vaginal vault and all were successfully salvaged with surgery. Our cohort for intermediate / high risk EC demonstrate a 88% (53 of 60 patients) relapse free survival which is broadly in line with PORTEC2 trial (78 – 83% for endometroid histology only). Tumour characteristics were broadly comparable by data we collected (See Figure 1). Recently, PORTEC3 reported a 76% failure free survival with chemo-radiotherapy (CRT) and 69% with radiotherapy at 5 years. We looked at 55 patients treated locally with high risk disease and found a 76% (42 of 55 patients) failure free survival rate, those patients were treated with a mixture of CRT, external beam radiotherapy, VT and adjuvant chemotherapy. (See Figure 2 for Kaplan– Meier curves for CRT with or without adjuvant chemotherapy versus radiotherapy alone). However of those with high risk disease only 4 had chemo- radiotherapy per PORTEC3 protocol (two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). Conclusion We conclude that broadly our relapse rate for endometrial cancer are in line with those published in the seminal studies. Importantly, when our cohort of high risk disease was compared to PORTEC3 data (ASCO June 2017), real life data is demonstrated. Only 4 if 55 patients received chemo-radiotherapy as per the PORTEC3 trail protocol because many patients could not be offered toxic CRT due to co-morbidities. EP-1503 Brachytherapy versus EBRT boost for cervical cancer: is the standard better? D. Delgado 1 , A. Figueiredo 1 , J. Leitão Santos 1 , A. Florindo 1 , V. Mendonça 1 , M. Lemos 1 , M. Abdulrehman 1 , M.F. De Pina 1 1 Centro Hospitalar Lisboa Norte EPE, Serviço de Radioterapia, Lisbon, Portugal Purpose or Objective Compare the outcomes of intracavity high-dose-rate brachytherapy (IC BT-HDR) boost and external beam radiotherapy (EBRT) boost of patients (pts) treated with concomitant chemoradiotherapy (CCRT) for cervical cancer. Material and Methods Retrospective review of 92 pts with stage IB1-IVA cervical cancer treated with CCRT between 2008 and 2013 with at least 1 year follow-up. All pts received pelvic 3D- conformal EBRT (45-50,4Gy) concomitant with weekly cisplatin (40mg/m2) and an IC BT-HDR boost (24Gy/4 fractions prescribed to point A-A’) to the tumor or a 3D- conformal EBRT boost (16,2Gy) if the former was not technically feasible. Pts with clinically positive paraaortic (PA) lymph nodes received PA lymph node irradiation. Parametrial EBRT boost was given when appropriate. Pts treated with at least one fraction of BT were included in the IC BT-HDR group. Characteristics of pts treated with and without IC BT-HDR were compared to evaluate for differences. The effect of the IC BT-HDR boost on recurrence free survival (RFS) and overall survival (OS) was examined with univariate and multivariate analyses. Results Median age of all pts was 52 years (24-83). IC BT-HDR boost was given to 37 pts (40,2%) and an EBRT boost to 55 pts (59,8%). Patients treated with EBRT boost had larger tumors (mean 53mm vs 39mm - p <0,001) and more advanced disease at diagnosis (FIGO stage >IIB 38,2% vs 5,4% - p <0,001), however roughly the same number of pts had stage <=IIB (34 vs 35pts). There was no difference in age or clinically positive lymph nodes at diagnosis. Ten pts (10,8%) received PA lymph node irradiation. Parametrial EBRT boost was given to 26 pts (74,6%) treated with IC BT-HDR boost. Median treatment time was

nodes affectation was found to be statistically significant in prognosis prediction (p=0.003). OS at 5yrs. was 73.7%. The 5-yrs OS for pts. with a SCC- Ag4.95ng/ml (84% Vs 63%, p=0.001). Pts. with tumour SUVmax level >/=16.35 presented worse OS, although it was not statistically significant (80 Vs 66%, p=0.21). When stratified pts. in four groups according to SCC-Ag and SUVmax level, the group with SCC-Ag>4.95ng/ml and SUVmax level>16.35 presented the worst OS at 5yrs (p=0.09). Details are shown in figure 1.

Conclusion SCC-Ag pretreatment level and tumor SUVmax value can be useful for prognosis prediction in LACC. Further studies are required to stablish the role of high level of both and if a more intensive therapy is required to this cohort. EP-1502 Endometrial cancer. Relapse free survival rates in our medium/large hospital in the UK L. Price 1 , R. Allerton 1 1 Royal Wolverhampton Hospital, Oncology, Wolverhampton, United Kingdom Purpose or Objective Endometrial cancer (EC) is common in developed countries (N. Colombo et al., 2013) and incidence is increasing in the UK and this is considered to be due to rising obesity rates (NCIN 2015), despite this survival rates have improved since 1990s (NCIN). Endometrial cancer treatment is guided by the risk of recurrence, low medium or high. Those with low-Intermediate risk Stage 1 disease have been shown to benefit from Radiotherapy following hysterectomy (PORTEC1). PORTEC2 looked at those with intermediate-high risk EC and demonstrated external radiotherapy is equivalent to vaginal brachytherapy (VT). Adjuvant Chemotherapy can be offered to those with high risk EC with Stage I-III any histology and no residual disease. (NSGO-9501/EORTC 55991 trial and MaNGO ILIADE III-study) Our objective was to assess local outcomes of relapse free survival for those with low, intermediate and high risk EC treated in our local medium/large district general hospital and compare with published relapse free survival data from large multi-centre clinical trials, PORTEC1, 2 and 3. Material and Methods 179 patients with EC discussed at multi-disciplinary meetings (MDT) and actively treated between May 2010 to November 2013 were assessed retrospectively using electronic notes. Patients were followed up for a median of 4 years and 1 month (the minimum follow up was 3 years 3 months with the maximum follow up being 6 years 11 months). Results Our cohort for low risk EC demonstrate a relapse free survival of 95% (62 of 64 patients) which is the same as that quoted by PORTEC1. All relapses were local relapses